QDENGA Becomes India’s First Approved Dengue Vaccine

Kolkata, July 20, 2026: Takeda Biopharmaceuticals India today announced that the Drug Controller General of India (DCGI) has granted market authorization for QDENGA (TAK-003), making it the first dengue vaccine to be approved in India for the prevention of dengue disease in individuals aged 4–60 years.QDENGA is designed to protect against all four dengue virus serotypes and can be administered regardless of prior dengue exposure, without the need for pre-vaccination testing. The approval comes at a critical time as dengue continues to pose a major public health challenge in India, which accounts for nearly one-third of the global dengue burden.”Dengue is a growing public health challenge, and India needs sustained, evidence-based prevention,” said Dr. Mahender Nayak, Head of Intercontinental Markets, Takeda. “The approval of QDENGA marks an important step forward in strengthening dengue prevention in India. We remain committed to working with public health authorities, healthcare professionals and partners to support equitable and sustainable access.”Peter Streibl, General Manager, Southeast Asia and India Cluster, Takeda, said, “Dengue is a shared regional challenge that requires collaboration across governments, healthcare professionals and communities. We aim to contribute to sustainable, evidence-based solutions that reflect the needs of each country.””India carries a substantial dengue burden, with all four dengue virus serotypes co-circulating in several regions,” said Dr. Goh Choo Beng, Medical Affairs Head, Southeast Asia & India Cluster. “QDENGA is designed to protect against all four serotypes, regardless of prior exposure, and its approval strengthens India’s comprehensive approach to dengue prevention.”QDENGA is approved in 43 countries, has WHO prequalification, and has seen more than 32 million doses distributed globally through public and private immunization programmes.